openPR Logo
Press release

Blood Cancer Drugs Market Share 2018: Global Industry Key Players- Amgen Inc, Bayer, AbbVie Inc, Roche Holding, Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline, Eli Lily & Co.

10-26-2018 03:25 PM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

Blood Cancer Drugs Market

Blood Cancer Drugs Market

According to the new market research “Global Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025", The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 from USD 24.3 Billion in 2017, at a CAGR of 11.1%."

Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-free-sample

Some of the major key players operating in global Blood Cancer Drugs Market:

Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs

The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

Make Inquiry about this report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/inquire-before-buying

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market.

On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

View more detailed TOC @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market.

Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

Customized Research Report As per your Requirements: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-customization

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact us

Mr. Neel
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: neel@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Blood Cancer Drugs Market Share 2018: Global Industry Key Players- Amgen Inc, Bayer, AbbVie Inc, Roche Holding, Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline, Eli Lily & Co. here

News-ID: 1332278 • Views: 283

More Releases from Polaris Market Research & Consulting

What's driving the Blockchain Technology Market Trends? Microsoft Corporation, I …
The worldwide market size for blockchain technology is estimated to grow at a CAGR of 41.6% between 2018 and 2026 and is anticipated to reach USD 16.82 billion by 2026. According to a new study published by Polaris Market Research. Also termed as Distributed Ledger Technology (DLT), blockchain enables secure transaction over a distributed network. Since the transactions are taken place usually over the network, it is difficult to reverse
What's driving the Precision Farming Market Trends? Ag Leader Technology, AgJunc …
The global precision farming/agriculture market was valued at 3,833 million in 2017 and is anticipated to reach over USD 13,016 million by 2026 with grow at a CAGR of more than 14.7% during the forecast period According to a new study published by Polaris Market Research. In 2017, the yield monitoring application dominated the global market, in terms of revenue. North America is expected to be the leading contributor to
What are the different trends in Electric Vehicles (EV) Market to boost its grow …
Polaris Market Research has new report published the addition of the “The global Electric Vehicles Market Worth $912 Billion By 2026 | CAGR: 38.4%”, the report classifies the global Electric Vehicles market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth Get PDF Sample of “Electric Vehicles Market”: https://www.polarismarketresearch.com/industry-analysis/electric-vehicles-ev-market/request-for-sample The global electric vehicles market is anticipated to
What are the different trends in Third Party Logistics Market to boost its growt …
Polaris Market Research has new report published the addition of the “The global third-party logistics market is anticipated to reach USD 1,337.91 billion by 2026”, the report classifies the global third-party logistics market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth according to a new report The report “Third Party Logistics (3PL) Market Share, Size,

All 5 Releases


More Releases for Blood

Blood Donation Chair
Blood Donation Chair Size: 190 L * 92 W * 135 - 164 H cm Back plate, the angle of inclination of the leg plate. Height adjustment. The adjustments are all electrically controlled and easy to operate. This product comes with three LINAK motors Maximum load capacity: 240 kg Optional: CPR function, weighing function The marketplace was wholly developed by the Jiangsu Medwish Network Technology Co., Ltd., a private corporation based in Jiangsu,
Blood Group Typing Market Banks on Increasing Need for Blood, Blood Products, an …
The global blood group typing market is foreseen to garner a massive demand in the foreseeable future owing to certain factors such as the rising demand for blood and blood products. Nonetheless, the market growth could see an escalation on the back of other factors such as increasing prenatal testing which requires blood grouping, mounting count of road mishaps and trauma incidences requiring blood transfusion, and increasing application in forensic
Artificial Blood Market Development
Artificial Blood Market Potential According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Use of stem cells from cord blood is increasing, as it does not require perfect human leukocyte antigen (HLA) tissue matching, can be used allogenically, and has less incidence of graft v/s host disease. According to the New
Blood Group Typing Market Banks on Increasing Need for Blood, Blood Products, an …
The global blood group typing market is foreseen to garner a massive demand in the foreseeable future owing to certain factors such as the rising demand for blood and blood products. Nonetheless, the market growth could see an escalation on the back of other factors such as increasing prenatal testing which requires blood grouping, mounting count of road mishaps and trauma incidences requiring blood transfusion, and increasing application in forensic
Blood Bank Market 2017
ReportsWeb.com has announced the addition of the “Global Blood Bank Market Research Report 2017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. Blood Bank industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and
Artificial Blood Market
Artificial blood is an artificially developed substitute for red blood cells. For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors. Transfusion of red blood cells (RBCs) is a standard